A Covid-19 treatment plan slowly emerges | Evaluate
Mateon Halts Lead Candidate Development, Axes 60% of Workforce
About Us – Oncotelic
Windlas Biotech, Mateon Therapeutics launch integrated solution for respiratory wellness in India
Mateon Therapeutics
Mateon Therapeutics Announces Termination of FOCUS Study in
Windlas Biotech, Mateon Therapeutics bring lung therapy food supplement PulmoHeal - FFOODS Spectrum - Unleashing the Power of Food Science & Technology
EX-4.1
MATN: Positive Early Results for ARTIVeda™ in Treating COVID-19…
DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST
Windlas Biotech and Mateon Therapeutics launch first-ever Drug-Device Lung Therapy Combined AI 360 platform for respiratory wellness - The Statesman
Windlas Biotech and Mateon Therapeutics to launch combined lung therapy, AI Telemedicine solution - Express Healthcare
Mateon Completes Its Acquisition of PointR Data Inc. - DATAVERSITY
NantCell Binding Termsheet | MATEON THERAPEUTICS INC | Business Contracts | Justia
Mateon Therapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
Blockchain-Fueled Company Mateon Develops Phase 3 Clinical Drug Candidate, Against COVID-19 - OT-101 – Blockchain News, Opinion, TV and Jobs
iBio Announces Collaboration with EdgePoint AI for Next Gen Biologics Manufacturing - DATAVERSITY
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
Keeping an eye on Mateon Therapeutics (OTCQB: MATN) says GEN - Genetic Engineering & Biotechnology News - EmergingGrowth.com
EDGAR Filing Documents for 0001493152-21-001207
Articles about Mateon Therapeutics, Inc.
Mateon Therapeutics
